Grifols Overview
- Year Founded
-
1909
- Status
-
Public
- Employees
-
25,247
- Stock Symbol
-
GRF
- Investments
-
57
- Share Price
-
$12.87
- (As of Friday Closing)
Grifols General Information
Description
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
Contact Information
Website
www.grifols.comCorporate Office
- Parque Empresarial Can Sant Joan
- Avinguda de la Generalitat, 152-158, Sant Cugat del Vallès
- 08174 Barcelona
- Spain
Corporate Office
- Parque Empresarial Can Sant Joan
- Avinguda de la Generalitat, 152-158, Sant Cugat del Vallès
- 08174 Barcelona
- Spain
Grifols Timeline
Grifols Stock Performance
As of 13-Nov-2026, Grifols’s stock price is $12.87. Its current market cap is $7.69B with 681M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $12.87 | $12.94 | $9.75 - $13.66 | $7.69B | 681M | 1.5M | $0.83 |
Grifols Financials Summary
As of 30-Sep-2026, Grifols has a trailing 12-month revenue of $8.83B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 18,304,993 | 20,872,059 | 18,077,388 | 24,547,366 |
| Revenue | 8,825,477 | 8,487,118 | 7,804,097 | 7,133,041 |
| EBITDA | 1,867,107 | 1,812,706 | 1,558,222 | 1,196,775 |
| Net Income | 568,149 | 453,458 | 169,890 | 45,447 |
| Total Assets | 22,999,025 | 23,154,086 | 22,273,441 | 23,204,668 |
| Total Debt | 10,478,329 | 11,236,404 | 10,523,304 | 12,129,501 |
Grifols Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Grifols Comparisons
Industry
Financing
Details
Grifols Competitors (44)
One of Grifols’s 44 competitors is Cipla, a Corporation company based in Mumbai, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cipla | Corporation | Mumbai, India | ||||
| Taibang Biological Group | Private Equity-Backed | Beijing, China | ||||
| Novartis | Corporation | Basel, Switzerland | ||||
| Rockwell Medical | Corporation | Wixom, MI | ||||
| Biocon | Formerly PE-Backed | Bengaluru, India |
Grifols Patents
Grifols Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026234263-A1 | Α1-antitrypsin with improved properties | Pending | 08-May-2025 | ||
| WO-2026233533-A1 | Supervised aggregation system and method for preparing an aggregation which uses the same | Pending | 05-May-2025 | ||
| WO-2026190134-A1 | Methods for producing immunoglobulin preparations | Pending | 10-Mar-2025 | ||
| WO-2026139520-A1 | A composition | Pending | 26-Dec-2024 | ||
| WO-2026027453-A1 | Device and method for printing paste and liquid material | Pending | 02-Aug-2024 | B33Y10/00 |
Grifols Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Grifols Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Grifols Investments & Acquisitions (57)
Grifols’s most recent deal was a Merger/Acquisition with Canadian Plasma Resources. The deal was made on 08-Jun-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Canadian Plasma Resources | 08-Jun-2026 | Merger/Acquisition | Other Healthcare Services | ||
| SoundStorming | 31-Dec-2025 | Early Stage VC | Entertainment Software | ||
| Biotest | 11-Jun-2025 | PIPE | Drug Discovery | ||
| Immunotek (14 Plasma Collection Centers in the United States) | 03-Feb-2025 | Corporate Asset Purchase | Buildings and Property | ||
| Bloodbuy | 11-Jul-2024 | Corporate | Other Healthcare Services |
Grifols ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
13.55 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Grifols Exits (7)
Grifols’s most recent exit was on 09-Nov-2020 from MedKeeper. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| MedKeeper | 09-Nov-2020 | Completed |
|
||
| Grifols Plasma | 01-Aug-2018 | Completed |
|
||
| Haema | 04-Jun-2018 | Completed |
|
||
| MedKeeper | 26-Jan-2018 | Completed |
|
||
| Singulex | 17-May-2016 | Later Stage VC | Completed |
Grifols Affiliates
Subsidiaries (13)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Freedom Plasma | St. Petersburg, FL | 2021 | |
| Grifols Canada Therapeutics | Saint-Laurent, Canada | 2015 | |
| Grifols Canada Plasma | Winnipeg, Canada | 2015 | |
| Alkahest | San Carlos, CA | 2014 | |
| Medcom Advance | Tarragona, Spain | 2013 |
Grifols FAQs
-
When was Grifols founded?
Grifols was founded in 1909.
-
Where is Grifols headquartered?
Grifols is headquartered in Barcelona, Spain.
-
What is the size of Grifols?
Grifols has 25,247 total employees.
-
What industry is Grifols in?
Grifols’s primary industry is Pharmaceuticals.
-
Is Grifols a private or public company?
Grifols is a Public company.
-
What is Grifols’s stock symbol?
The ticker symbol for Grifols is GRF.
-
What is the current stock price of Grifols?
As of 13-Nov-2026 the stock price of Grifols is $12.87.
-
What is the current market cap of Grifols?
The current market capitalization of Grifols is $7.69B.
-
What is Grifols’s current revenue?
The trailing twelve month revenue for Grifols is $8.83B.
-
Who are Grifols’s competitors?
Cipla, Taibang Biological Group, Novartis, Rockwell Medical, and Biocon are some of the 44 competitors of Grifols.
-
What is Grifols’s annual earnings per share (EPS)?
Grifols’s EPS for 12 months was $0.83.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
